Themis Medicare Limited's Preferential Issue Committee held a crucial meeting on February 25, 2026, to deliberate on the company's proposed preferential issue of convertible equity warrants. The committee, constituted by the Board of Directors, approved key decisions regarding the allotment and pricing of these financial instruments.

Warrant Allotment Details

The committee approved the allotment of convertible equity warrants to Vividhmargi Investments Private Limited, a decision that builds upon the Board's earlier approval from February 13, 2026. The pricing structure was established based on professional certification and regulatory compliance requirements.

Regulatory Compliance and Pricing

The committee noted the pricing certificate issued by Mr. Abhishek Wagh, Proprietor of M/s. Abhishek Wagh & Associates, Practicing Company Secretaries. This certificate indicated the minimum issue price of Rs. 99.76 in accordance with Regulation 164 of the SEBI (ICDR) Regulations, 2018. The committee subsequently approved rounding up this price to Rs. 100.00 per convertible equity warrant for practical implementation.

Postal Ballot Schedule

The committee approved the Notice of Postal Ballot to seek shareholder approval for the preferential issue. The approval process is subject to consent from both shareholders and stock exchanges, reflecting the company's commitment to regulatory compliance.

Corporate Governance Framework

The meeting was conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's adherence to disclosure requirements. Chairman and Director Dinesh S. Patel signed the disclosure document, ensuring proper authorization and accountability in the decision-making process.

This preferential issue represents a significant corporate action for Themis Medicare Limited, requiring comprehensive stakeholder approval before implementation. The structured approach to pricing, allotment, and approval processes reflects the company's commitment to regulatory compliance and transparent corporate governance practices.

Themis Medicare Limited has announced a key management change with the resignation of its Company Secretary and Compliance Officer. The pharmaceutical company informed the stock exchanges about this corporate development under regulatory disclosure requirements.

Key Personnel Change

Mr. Pradeep M. Chandan has resigned from his position as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) of Themis Medicare Limited. The resignation became effective from February 13, 2026.

Regulatory Communication

The company formally communicated this development to both major stock exchanges on February 14, 2026. The notification was sent to BSE Limited (Scrip Code: 530199) and National Stock Exchange of India Limited (Symbol: THEMISMED) under reference number TML/BSE/NSE/2025-26/52.

Official Statement

In his resignation letter dated February 12, 2026, Mr. Chandan stated that he was resigning due to other professional commitments. He requested the Board of Directors to accept his resignation and relieve him from his position with immediate effect. The outgoing Company Secretary expressed sincere gratitude to the management and Board of Directors for their support, guidance, and cooperation during his tenure.

Company Leadership

The resignation notification was signed by Mr. Dinesh S. Patel, Chairman & Director (DIN: 00033273), confirming the company's compliance with regulatory disclosure requirements under Regulation 30. The company will need to appoint a new Company Secretary and Compliance Officer to fill the vacant positions in accordance with regulatory requirements.